Brief: XBiotech Announces Successful Completion Of Phase I Portion Of Pancreatic Cancer Study
20/06/2022 14:16
June 20 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES SUCCESSFUL COMPLETION OF PHASE I
PORTION OF
PANCREATIC CANCER STUDY
* XBIOTECH INC - ENROLLMENT IN PHASE II PORTION IS
COMMENCING
IMMEDIATELY FOR NATRUNIX
Source text for Eikon: ID:nGNX4Hyn20
Further company coverage: XBIT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke